The Bank of New York Mellon, the global asset management and securities servicing firm, has been selected by Biovitrum AB, a global pharmaceutical company, as the depositary bank for its American depositary receipt (ADR) program. Each Biovitrum ADR represents one ordinary share.
Martin Nicklasson, Chief Executive Officer of Biovitrum, said: “We wish to optimize US investor access to our company, and we believe The Bank of New York Mellon has the resources and expertise necessary to help us achieve that goal.”
Michael Cole-Fontayn, Chief Executive Officer of The Bank of New York Mellon’s Depositary Receipt Division, said: “We look forward to helping Biovitrum unlock the potential of the U.S. capital markets. The Bank of New York Mellon will utilize its resources to develop a long and mutually beneficial partnership with Biovitrum and its investors.”
